Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

被引：328

作者：

Knight, Steven D. ^{[1
]}

Adams, Nicholas D. ^{[1
]}

Burgess, JoeIle L. ^{[1
]}

Chaudhari, Amita M. ^{[1
]}

Darcy, Michael G. ^{[1
]}

Donatelli, Carla A. ^{[1
]}

Luengo, Juan I. ^{[1
]}

Newlander, Ken A. ^{[1
]}

Parrish, Cynthia A. ^{[1
]}

Ridgers, Lance H. ^{[1
]}

Sarpong, Martha A. ^{[1
]}

Schmidt, Stanley J. ^{[1
]}

Van Aller, Glenn S. ^{[1
]}

Carson, Jeffrey D. ^{[1
]}

Diamond, Melody A. ^{[1
]}

Elkins, Patricia A. ^{[1
]}

Gardiner, Christine M. ^{[1
]}

Garver, Eric ^{[1
]}

Gilbert, Seth A. ^{[1
]}

Gontarek, Richard R. ^{[1
]}

Jackson, Jeffrey R. ^{[1
]}

Kershner, Kevin L. ^{[1
]}

Luo, Lusong ^{[1
]}

Raha, Kaushik ^{[1
]}

Sherk, Christian S. ^{[1
]}

Sung, Chiu-Mei ^{[1
]}

Sutton, David ^{[1
]}

Tummino, Peter J. ^{[1
]}

Wegrzyn, Ronald J. ^{[1
]}

Auger, Kurt R. ^{[1
]}

Dhanak, Dashyant ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Collegeville, PA 19426 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2010年 / 1卷 / 01期

关键词：

GSK2126458; phosphoinositide 3-kinase alpha; mammalian target of rapamycin; PI3K/AKT pathway; CANCER-SPECIFIC MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASES; PIK3CA; PHOSPHORYLATION; IDENTIFICATION; P110-ALPHA; PATHWAY; CELL;

D O I：

10.1021/ml900028r

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Phosphomositide 3-kinase alpha (PI3K alpha) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3K alpha and mTOR with in vivo activity in both pharrnacodynamic and tumor growth efficacy models Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

引用

页码：39 / 43

页数：5

共 50 条

[31] Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
Han, Fangbin
Lin, Songwen
Liu, Peng
Liu, Xiujie
Tao, Jing
Deng, Xiaobing
Yi, Chongqin
Xu, Heng
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 434 - 438
[32] Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors
Terstiege, Ina
Perry, Matthew
Petersen, Jens
Tyrchan, Christian
Svensson, Tor
Lindmark, Helena
Oster, Linda
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (03) : 679 - 687
[33] PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
Venkatesan, Aranapakam M.
Chen, Zecheng
Dos Santos, Osvaldo
Dehnhardt, Christoph
Delos Santos, Efren
Ayral-Kaloustian, Semiramis
Mallon, Robert
Hollander, Irwin
Feldberg, Larry
Lucas, Judy
Yu, Ker
Chaudhary, Inder
Mansour, Tarek S.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) : 5869 - 5873
[34] Discovery of an irreversible PI3Kα-specific Inhibitor
Qiao, Lixin
Nacht, Mariana
Sheets, Michael P.
St Martin, Thia
Labenski, Matthew
Mazdiyasni, Hormoz
Zhu, Zhendong
Chaturvedi, Prasoon
Bhavsar, Deepa
Niu, Deqiang
Westlin, William
Petter, Russell
Singh, Juswinder
CANCER RESEARCH, 2011, 71
[35] Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).
Munster, P. N.
van der Noll, R.
Voest, E. E.
Dees, E. C.
Tan, A. R.
Specht, J. M.
Falchook, G. S.
Daud, A.
Lolkema, M. P.
Grilley-Olson, J. E.
Yu, E. Y.
Fu, S.
Bergsland, E. K.
Kleha, J.
Peng, S.
Smith, D. A.
Lampkin, T. A.
Schellens, J. H. M.
Morris, S. R.
Kurzrock, R.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[36] A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells.
Keles, Erhan
Borsari, Chiara
Sriramaratnam, Rohitha
Schafer, Thorsten
Wymann, Matthias P.
CANCER RESEARCH, 2021, 81 (13)
[37] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
Ma, Chen-Chen
Zhang, Cheng-Mei
Tang, Long-Qian
Liu, Zhao-Peng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17
[38] Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
Erra, Montse
Taltavull, Joan
Greco, Angelique
Javier Bernal, Francisco
Francisco Caturla, Juan
Gracia, Jordi
Dominguez, Maria
Sabate, Mar
Paris, Stephane
Soria, Salome
Hernandez, Begona
Armengol, Clara
Cabedo, Judit
Bravo, Monica
Calama, Elena
Miralpeix, Montserrat
Lehner, Martin D.
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 118 - 123
[39] Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers
Barlaam, Bernard
Cosulich, Sabina
Delouvrie, Benedicte
Fitzek, Martina
Germain, Herve
Green, Stephen
Harris, Craig S.
Hudson, Kevin
Lambert-van der Brempt, Christine
Lamorlette, Maryannick
Antoine, Le Griffon
Morgentin, Remy
Ouvry, Gilles
Page, Ken
Pasquet, Georges
Ruston, Linette
Saleh, Twana
Vautier, Michel
Ward, Lara
CANCER RESEARCH, 2015, 75
[40] Synthesis of PF-04691502, a highly potent PI3K/mTOR dual inhibitor
Hoffman, Jacqui
Bailey, Simon
Cheng, Hengmiao
Kania, Robert
Jai, Lei
Nambu, Mitch
Ninkovich, Sacha
Pairish, Mason
Srirangam, Jay
Wang, Xiaolong
Le, Phuong
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243

← 1 2 3 4 5 →